ArticleFrontiers in epigenetics and epigenomics2026
Arsenic induced Hippo pathway dysregulation linked to hTERT hypo-methylation in breast cancer patients.
Article in Frontiers in epigenetics and epigenomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: A key stage in the development of almost all types of malignancies is the dysregulation of telomeres and telomerase (hTERT). It has been suggested that arsenic-mediated changes in gene methylation status can mute tumor suppressor genes or increase oncogene expression, resulting in long-term alterations in the activity of genes governing cell transformation. Recent study demonstrated that, long-term exposure to an environmentally relevant dose of arsenic affects cellular development by interfering with the Hippo signaling system. The current study's objective is to ascertain the underlying molecular cause of arsenic induced telomerase alteration and how it is associated with gene methylation. Method: Twenty-eight female with intermittent breast cancer from arsenic exposed areas were selected, after surgery, a sample of the tumor and the healthy tissue (which serves as a control group) were extracted for further processing. Arsenic concentration was analyzed by atomic absorption spectrometry. Western blotting and RT-PCR were used to analyze the telomerase expression. Additionally, MS-PCR was used to identify the genetic and epigenetic changes, respectively. Result: According to our research, 65% of female breast cancer patients had extremely high arsenic concentrations with elevated telomerase expression. The cause of this up regulation of telomerase expression is hTERT promoter hypomethylation. Discussion: The findings also demonstrated a substantial association between breast cancer patients' upregulation of hTERT and their exposure to arsenic and fine-needle biopsy specimens may provide further predictive information. Higher telomerase expression was associated with a worse outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.